Azucena Ibeth Carballo Villalobos

Dr. Azucena Ibeth Carballo Villalobos

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in BioMed Research International
Verified
Journal Article
Open access
PDF file
AVAzucena Ibeth Carballo Villalobos
Azucena Ibeth Carballo Villalobos
MGMaría Eva González-Trujano
María Eva González-Trujano
FPFrancisco Pellicer
Francisco Pellicer
FLFrancisco J. López-Muñoz
Francisco J. López-Muñoz
Neuropathic pain is caused by a primary lesion, dysfunction, or transitory perturbation in the peripheral or central nervous system. In this study, we investigated the hesperidin antihyperalgesic effects alone or combined with diosmin in a model of neuropathic pain to corroborate a possible synergistic antinociceptive activity. Mechanical and thermal hyperalgesia were assessed in the aesthesiometer and plantar tests, respectively, after chronic constriction injury (CCI) model in rats receiving hesperidin (HS, 5 doses from 10 to 1000 mg/kg) alone or combined with diosmin (DS, 10 and 100 mg/kg) in comparison to gabapentin (31.6 mg/kg). UHPLC-MS analysis of cerebral samples was used to recognize the central concentrations of these flavonoids. Participation of different receptors was also investigated in the presence of haloperidol, bicuculline, and naloxone antagonists. Acute hesperidin administration significantly decreased mechanical and thermal hyperalgesia in CCI rats. Antihyperalgesic response of hesperidin, improved by a combination with diosmin (DS10/HS100) in both stimuli, was blockaded by haloperidol, bicuculline, and naloxone, but not WAY100635, antagonists. Both flavonoids were detected in brain samples. In conclusion, hesperidin alone and combined with diosmin produces antihyperalgesic response in the CCI model in rats. Antihyperalgesic effect of DS10/HS100 combination involves central activity partially modulated by D2,GABAA, and opioids, but not by 5-HT1A, receptors.

1 January 2018 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
AVAzucena Ibeth Carballo Villalobos
Azucena Ibeth Carballo Villalobos
MGMaría Eva González-Trujano
María Eva González-Trujano
FPFrancisco Pellicer
Francisco Pellicer
NANoe Alvarado-Vasquez
Noe Alvarado-Vasquez
FLFrancisco Javier López-Muñoz
Francisco Javier López-Muñoz

1 March 2010 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
AVAzucena Ibeth Carballo Villalobos
Azucena Ibeth Carballo Villalobos
AMAna Laura Martinez
Ana Laura Martinez
MGMa. Eva González-Trujano
Ma. Eva González-Trujano
FPFrancisco Pellicer
Francisco Pellicer
Rosa Ventura-MartinezRosa Ventura-Martinez
Rosa Ventura-Martinez
FLFrancisco J. López-Muñoz
Francisco J. López-Muñoz

5 August 2013 in European journal of pain
Verified
Journal Article
Closed access
PDF file
AVAzucena Ibeth Carballo Villalobos
Azucena Ibeth Carballo Villalobos
MGM.E. González‐Trujano
M.E. González‐Trujano
FLFrancisco Javier López-Muñoz
Francisco Javier López-Muñoz

1 November 2021 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
GEGonzález-Ramírez Adriana Estrella
González-Ramírez Adriana Estrella
MGMaría Eva González-Trujano
María Eva González-Trujano
Alberto Hernandez-LeonAlberto Hernandez-Leon
Alberto Hernandez-Leon
MVMARIA GUADALUPE VALLE-DORADO
MARIA GUADALUPE VALLE-DORADO
AVAzucena Ibeth Carballo Villalobos
Azucena Ibeth Carballo Villalobos
FLFrancisco Javier López-Muñoz
Francisco Javier López-Muñoz

1 November 2016 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
GABRIELA ÁVILA-VILLARREALGABRIELA ÁVILA-VILLARREAL
GABRIELA ÁVILA-VILLARREAL
MGMaría Eva González-Trujano
María Eva González-Trujano
AVAzucena Ibeth Carballo Villalobos
Azucena Ibeth Carballo Villalobos
AAA. Berenice Aguilar-Guadarrama
A. Berenice Aguilar-Guadarrama
SGSara García-Jiménez
Sara García-Jiménez
SESamuel Estrada-Soto
Samuel Estrada-Soto